IL2 and melanoma: In veterinary oncology, the situation is much more modest, with around a hundred publications on the subject and only two treatments approved for commercialization: a plasmid vector with the human tyrosinase gene as a xenoantigen for canine melanoma (OnceptTM Canine Melanoma Vaccine, Duluth, GA, USA) and a canarypox virus vector with the feline interleukin-2 gene for feline fibrosarcoma (Oncept IL-2TM).